Obesity Drug To Be Tested By Fda

07.13.10 | FL News Team

(Washington, DC)  --  Concern remains over a pill that has shown signs of helping overweight people drop pounds.  In documents made public on Tuesday, the Food and Drug Administration cites five areas of concern over the experimental obesity drug Qnexa.  Its maker, Vivus, is hoping the FDA will approve Onexa, which would make it the first new prescription weight loss drug in ten years.

The five areas the FDA is concerned about are:  Memory, attention span and language problems as well as an increased heart rate and a potential increase in body acids.  With up to two-thirds of Americans overweight, many have anticipated Onexa's release.  On Thursday an FDA panel will debate Onexa, and in October will make a final decision on the drug.